Randomised controlled trial to reduce morbidity of bronchiolitis in young children admitted to Royal Darwin hospital in the NT

Gabrielle Mccallum, I Versteegh, Carolyn MacLennan, Royal Hospital, Chee Wilson, Susan Pizzutto, Peter Morris, Anne Chang

Research output: Chapter in Book/Report/Conference proceedingConference Paper published in Proceedingspeer-review


Background / Purpose: Bronchiolitis is the most common reason for hospital admission for infants globally. The use of antibiotics, in particular macrolides for treating bronchiolitis in non affluent settings remains controversial but potentially beneficial. In our region, readmission with lower respiratory illness in young children, particularly Indigenous children remains high.To determine if a single dose of azithromycin reduces the morbidity of young children hospitalised with bronchiolitis.The combined anti-microbial and anti-inflammatory properties of a macrolide, (Azithromycin) will improve clinical outcomes for young children with moderate-severe bronchiolitis. Main conclusion: Double blind RCT. Young children <18 months admitted to Royal Darwin Hospital (RDH) diagnosed with bronchiolitis are eligible. Children are given a single dose (30mg/kg) of either azithromycin/placebo at enrolment.Recruitment for this study is ongoing. Results highlight that Indigenous children have longer hospitalisations, length of time requiring oxygen and number of co morbidities. Reducing the burden of ongoing respiratory illness in this population is important.
Original languageUndefined
Title of host publicationThoracic Society of Australia and New Zealand Annual Scientific Meeting 2011
Number of pages1
Publication statusPublished - 1 May 2011

Cite this